Duquesne, the family office of renowned investor Stanley Druckenmiller, has listed healthcare diagnostics company Natera (NASDAQ: NTRA) as its largest holding for eight consecutive quarters. Natera specializes in liquid biopsy technology, with oncology test volumes growing 57% year-over-year to approximately 296,700 in Q2, and total test volumes increasing over 22% to more than 1 million. Revenue for the quarter rose 38%, and net loss narrowed from nearly $101 million in the same period last year to less than $67 million. In June, the company received regulatory approval in Japan for its Signatera test for colorectal cancer screening. As of the end of June, Natera held nearly $1.1 billion in cash and expects to achieve positive free cash flow for the full year 2026. The article's author believes that Natera's stock, which has risen 87% over the past year, has a high valuation but still has room for upside.